JP2022514569A5 - - Google Patents
Info
- Publication number
- JP2022514569A5 JP2022514569A5 JP2021535041A JP2021535041A JP2022514569A5 JP 2022514569 A5 JP2022514569 A5 JP 2022514569A5 JP 2021535041 A JP2021535041 A JP 2021535041A JP 2021535041 A JP2021535041 A JP 2021535041A JP 2022514569 A5 JP2022514569 A5 JP 2022514569A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- pharmaceutically acceptable
- use according
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783947P | 2018-12-21 | 2018-12-21 | |
| US62/783,947 | 2018-12-21 | ||
| PCT/US2019/068094 WO2020132594A1 (en) | 2018-12-21 | 2019-12-20 | Amorphous sparsentan compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514569A JP2022514569A (ja) | 2022-02-14 |
| JP2022514569A5 true JP2022514569A5 (enExample) | 2022-11-29 |
Family
ID=69187971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535041A Pending JP2022514569A (ja) | 2018-12-21 | 2019-12-20 | 非晶質スパルセンタン組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220048900A1 (enExample) |
| EP (1) | EP3897834A1 (enExample) |
| JP (1) | JP2022514569A (enExample) |
| KR (1) | KR20210125994A (enExample) |
| CN (1) | CN114126712A (enExample) |
| AU (1) | AU2019404552A1 (enExample) |
| BR (1) | BR112021012226A2 (enExample) |
| CA (1) | CA3124127A1 (enExample) |
| IL (1) | IL284186A (enExample) |
| MA (1) | MA54542A (enExample) |
| MX (1) | MX2021007258A (enExample) |
| WO (1) | WO2020132594A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53817A (fr) | 2018-10-04 | 2021-08-11 | Travere Therapeutics Inc | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv |
| WO2022266370A1 (en) | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| MX2024007184A (es) * | 2021-12-28 | 2024-06-26 | Alchemedicine Inc | Compuesto, antagonista del receptor tipo 1 de angiotensina ii y composicion farmaceutica. |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
| CN120752231A (zh) * | 2023-02-24 | 2025-10-03 | 江苏豪森药业集团有限公司 | 含芳环类衍生物拮抗剂的盐、其制备方法和应用 |
| CN118666826A (zh) * | 2024-08-23 | 2024-09-20 | 成都臻拓医药科技有限公司 | 一种司帕生坦原料药的重结晶纯化方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| EP1741713A3 (en) * | 1999-12-15 | 2009-09-09 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| DK3222277T3 (da) * | 2009-03-31 | 2020-05-11 | Ligand Pharm Inc | Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati |
| WO2010135350A2 (en) * | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| MA46524A (fr) * | 2016-10-13 | 2019-08-21 | Retrophin Inc | Composés de biphényl-sulfonamide destinés au traitement de néphropathies |
-
2019
- 2019-12-20 US US17/415,518 patent/US20220048900A1/en not_active Abandoned
- 2019-12-20 KR KR1020217021973A patent/KR20210125994A/ko not_active Ceased
- 2019-12-20 WO PCT/US2019/068094 patent/WO2020132594A1/en not_active Ceased
- 2019-12-20 MX MX2021007258A patent/MX2021007258A/es unknown
- 2019-12-20 MA MA054542A patent/MA54542A/fr unknown
- 2019-12-20 CA CA3124127A patent/CA3124127A1/en active Pending
- 2019-12-20 EP EP19842514.2A patent/EP3897834A1/en not_active Withdrawn
- 2019-12-20 CN CN201980092448.1A patent/CN114126712A/zh active Pending
- 2019-12-20 JP JP2021535041A patent/JP2022514569A/ja active Pending
- 2019-12-20 BR BR112021012226-5A patent/BR112021012226A2/pt not_active IP Right Cessation
- 2019-12-20 AU AU2019404552A patent/AU2019404552A1/en not_active Abandoned
-
2021
- 2021-06-20 IL IL284186A patent/IL284186A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530713A5 (enExample) | ||
| JP2011511754A5 (enExample) | ||
| JP2017523206A5 (enExample) | ||
| KR102528435B1 (ko) | 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물 | |
| RU2017106795A (ru) | Новые составы ингибитора тирозинкиназы брутона | |
| JP2012224641A (ja) | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 | |
| JP2019519581A5 (enExample) | ||
| CN109431966B (zh) | 依达拉奉药物组合物 | |
| WO2001095912A1 (fr) | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph | |
| JP2013503893A5 (enExample) | ||
| JP2015504073A5 (enExample) | ||
| CN102946871A (zh) | 曲马多和昔布类（Coxibs）的共晶体的药物组合物 | |
| TW201328722A (zh) | 醫藥調配物 | |
| JP2022533968A5 (enExample) | ||
| JP2022514569A (ja) | 非晶質スパルセンタン組成物 | |
| JP2019520344A5 (enExample) | ||
| RU2014114499A (ru) | Препараты {2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил}амида циклопропанкарбоновой кислоты | |
| US20220339141A1 (en) | Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein | |
| JP2021512921A5 (enExample) | ||
| JP2025502064A5 (enExample) | ||
| JP2020536098A5 (enExample) | ||
| JP2022514152A5 (enExample) | ||
| ES2674811T3 (es) | Composiciones estables de fesoterodina | |
| CN114585362A (zh) | 治疗制剂及其用途 | |
| JP2021501202A5 (enExample) |